Comparing the effects of Sitagliptin and Empagliflozin on blood glucose, lipid profiles, bloodpressure and body mass index in type2 dibetics patients treated with Metformin

Abstract

Type 2 diabetes is characterized by resistance to insulin function due to abnormalities in the metabolic processes of sugars in insulin receptors or pre-receptor processes, as well as intracellular messaging mechanisms and eventual destruction of pancreatic beta cells or insulin secretion. Metformin is one of the first-line drugs for treatment, which, if not affected well, can be combined with new-generation drugs such as Empagliflozin and Sitagliptin to show more excellent and faster recovery. The aim of this study was to use the drugs ampagliflozin and sitagliptin due to better efficacy in diabetic patients. Methods: A total of 91 people divided into two groups of 46, and 45 with a mean age of 53 were included in the study with a personal consent form and were treated separately with two drugs, Sitagliptin, and Empagliflozin, simultaneously with metformin or metformin and sulfonylurea for three months. Body mass index, lipid profile, fasting blood sugar, and 2hpp were measured and recorded two hours later and patients' blood pressure before and after the study. Results: both groups had experienced no significant P-value for Lipid profile, and FBS, 2hpp (P=0.445; P=0.48; P= 0.527; P=0.165; P= 785 respectively). But Hba1, BMI, Systolic and Diastolic blood pressure had significant changes (P<0.001; P<0.041; P<0.001; P<0.001; respectively).